Chlorozotocin treatment of advanced gastrointestinal cancer

A. Veronesi, M. D. Magri, U. Tirelli, E. Galligioni, F. Figoli, V. Zagonel, S. Tumolo, E. Grigoletto

Research output: Contribution to journalArticlepeer-review


From April 1981 to December 1981, 34 consecutive patients with advanced gastrointestinal cancer were treated with chlorozotocin at the dosage of 40 mg/m2 daily for 5 consecutive days (30 mg/m2 in patients pretreated with chemotherapy) every 6 weeks. In the 30 patients evaluable for response, a 3.3% objective response rate was encountered. Toxicity was not significant and consisted mainly in reversible myelosupression. Median survival was 3 months. At the dosage and schedule used, chorozotocin does not seem to be an effective agent in the treatment of advanced gastrointestinal cancer.

Original languageEnglish
Pages (from-to)365-366
Number of pages2
JournalMedical and Pediatric Oncology
Issue number5
Publication statusPublished - 1983

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Chlorozotocin treatment of advanced gastrointestinal cancer'. Together they form a unique fingerprint.

Cite this